期刊文献+

Survivin和PTEN在膀胱癌组织中的表达及临床意义 被引量:1

Expression and significance of survivin protein, PTEN in bladder transitional cell carcinomas
下载PDF
导出
摘要 目的研究凋亡抑制基因Survivin和抑癌基因PTEN在膀胱移行细胞癌(BTCC)中的表达及其与肿瘤分级、分期的关系。方法应用免疫组织化学方法,检测60例膀胱移行细胞癌和10例正常膀胱黏膜组织中Survivin蛋白和PTEN的表达。结果60例BTCC中Survivin蛋白的表达率为76.67%,10例正常膀胱组织中未见Survivin蛋白表达,Survivin蛋白表达随BTCC分级、分期的增高而增高。Survivin蛋白在各级肿瘤中表达Ⅰ级42.86%,Ⅱ级79.17%,Ⅲ级95.45%;浅表性癌表达率55.56%,浸润性癌表达率为85.71%,初发63.64%,复发92.59%,单发61.54%,多发88.24%;初发与复发,单发与多发之间表达具有统计学意义(P<0.05)。PTEN蛋白在60例膀胱移行细胞癌组织中阳性表达率为31.67%,PTEN阳性表达率随肿瘤细胞病理分级、临床分期程度的增高呈下降趋势。10例正常膀胱组织中PTEN蛋白均呈阳性反应。结论Survivin蛋白和PTEN的表达与BTCC临床病理特征和生物学行为有密切关系,联合检测Survivin和PTEN,对诊断BTCC、判断其恶性程度及预后均有一定参考价值。 Objective To study the expression of survivin, PTEN in BTCC and its relationship between tissue grade and pathology stage. Methods The immunohistological staining was used to evaluated the expression of survivin protein and PTEN in 60 cases of transitional cell carcinoma of urinary bladder and 10 normal bladder mucosa. Results The positive rate of survivin protein in BTCC was 76.67%, expression of survivin protein in 10 normal mucosa was negative; In BTCC, grade Ⅰ 42.86%, Ⅱ 79.17%, Ⅲ 95.45% ; in stage of T1 ,T2-3 are 55.56% ,85.71% respectively; and in primary,recurrent cases are 63.64%, 92.59% (P 〈 0.05) respectively. The positive rate of PTEN was 31.67%, the higher the grade and the clinical stage of tumors, the lower the expression of PTEN, 10 normal bladder mucosa was positive. Conclusion The positive correlation was found between the abnormal expression of survivin protein, PTEN and the behavior in biology of the transitional cell carcinoma of the bladder. The coexpression of survivin and PTEN have the synergism in diagnosis, malignant degree and prognosis in BTCC.
出处 《实用肿瘤学杂志》 CAS 2006年第4期270-273,共4页 Practical Oncology Journal
关键词 SURVIVIN PTEN 膀胱肿瘤 免疫组织化学 Survivin PTEN Bladder neoplasms Immunohistochemistry
  • 相关文献

参考文献9

  • 1Li J,Yen C,Liaw D,et al.PTEN:a putative protein tyrosine phosphotase gene mutated in human brain,breast and prostated cancer[J].Science,1997;275:1943~1947
  • 2Aveyard JS,SkilIeter A,Habuchi T,et al.Somatic mutation of PTEN in bladder carcinoma[J].Br J Cancer,1999;80(5-6);904~908
  • 3Tanaka M,Koul D,Davies MA,et al.MMACI/PTEN inhibits cell growth and induceschemosensitivity to doxorubicin in human bladder cancer cells[J].Oncogene,2000;19(47):5406~5412
  • 4Ambrosini G,Adida C,Altieri DC.A novel anti-apoptosis gene,surviving,expressed in cancer and lymphoma[J].Nat Med,1997;3(8):917~921
  • 5Bao R,Connolly DC,Murphy M,et al.Activation of cancer gene specific gene expression by the survivirig promotbr[J].J Natl Cancer Inst,2002;94(7):522
  • 6Conway EM,Pollefeyt S,Cornelissen J,et al.Three differentially expressed surviving cDNA variants encode proteins with distinct antiapoptosis function[J].Blood,2000;95:1435~42
  • 7OConnor DS,Schechner JS,Adida C,et al.Control of apoptosis during angiogenesis by surviving express in endothelial cell[J].Am J Pathol,2000;156(2):393
  • 8Carter BZ,Milella M,Altieri DC,et al.Cytokine-regulated expression of surviving in myeloid leukemia[J].Blood,2001;97(9):2784~2790
  • 9Suzuki A,Hayashida M,Ito T,et al.Survivin initiates cell cycleentry by the competitive interaction with Cdk4/p16 (INK4a) and Cdk2/CyclinE complex activation[J].Oncogene,2000;19(29):3225~3234

同被引文献12

  • 1Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [ J]. Science, 1997, 275 (5308) :1943 - 1947.
  • 2Steck PA ,Pershouse MA ,Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23. 3 that is mutated in multiple advanced cancers [ J ]. Nat Genet, 1997,15 ( 4 ) : 356 - 362.
  • 3Li DM, Sun H. TEPI, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta [ J ]. Cancer Res, 1997,57( 11 ) :2124 -2129.
  • 4Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, et al. Inactivation of p53 and PTEN promotes invasive bladder cancer [J]. Genes Dev,2009,23(6) :655 -659.
  • 5Hager M, Haufe H, Kemmerling R, et al. PTEN expression in renal cell carcinoma and oncocytoma and prognosis [ J ]. Pathology,2007,39 ( 5 ) :482 - 485.
  • 6Sano T, Lin H, Chen X, et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis [ J ]. Cancer Res, 1999,59 ( 8 ) : 1820 - 1824.
  • 7Qian CN, Furge KA, Knol J, et al. Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis : identification in human tumors and confirmation in animal models [ J ]. Cancer Res, 2009, 69 (21) : 8256 - 8264.
  • 8He L, Fan C, Gillis A, et al. Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma [ J]. Biochem Biophys Acta,2007, 1772(10) :1134 - 1142.
  • 9Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers [ J]. J Natl Cancer Inst,2000,92 ( 11 ) : 924 - 930.
  • 10Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens [ J]. Nat Med, 1998,4(7 ) :844 - 847.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部